What is the recommended workup and treatment for a patient with left upper quadrant abdominal pain and nausea, without vomiting, fever, weight loss, or bowel habit changes, who has recently started a probiotic?

Initial Workup and Management for Left Upper Quadrant Pain with Nausea

For a patient with left upper quadrant pain and nausea without alarm features (no fever, weight loss, or bowel habit changes), the most appropriate initial approach is to obtain basic laboratory testing and consider CT imaging with IV contrast to exclude serious pathology, while recognizing that functional disorders like IBS or functional dyspepsia are the most likely diagnoses.

Immediate Diagnostic Considerations

Rule Out Serious Pathology First

Left upper quadrant pain requires consideration of both organ-specific and referred causes 1, 2. The absence of fever, weight loss, and bowel habit changes is reassuring but does not exclude significant pathology. CT with IV contrast is the preferred imaging modality for left upper quadrant pain when clinical evaluation is inconclusive 1, 2.

Key structures to evaluate include:

• Spleen: infarction, rupture, or enlargement
• Stomach/duodenum: peptic ulcer disease, gastritis
• Pancreas: pancreatitis (tail)
• Left kidney: pyelonephritis, urolithiasis
• Splenic flexure: colitis, diverticulitis

Essential Laboratory Testing

Obtain the following to guide diagnosis 2:

• Complete blood count (evaluate for infection, anemia)
• C-reactive protein (inflammatory marker)
• Lipase (pancreatic pathology)
• Hepatobiliary markers (referred pain from liver/biliary system)
• Urinalysis (renal pathology)
• Pregnancy test if applicable

Most Likely Diagnosis: Functional Disorder

Given the symptom profile—LUQ pain with nausea, improvement in bowel movements with probiotics, and absence of alarm features—this presentation is most consistent with either IBS or functional dyspepsia 3, 4.

Functional Dyspepsia Considerations

The combination of upper abdominal discomfort with nausea suggests functional dyspepsia, which arises from gut-brain axis dysfunction 4. The British Society of Gastroenterology 2022 guidelines emphasize that normal test results do not mean absence of pathology—they indicate functional issues with stomach sensitivity and motility 4.

IBS Considerations

If symptoms include altered bowel patterns (even if subtle), IBS becomes more likely. The recent probiotic use with bowel movement improvement supports this diagnosis 3.

Treatment Algorithm

Step 1: Test for H. pylori

All patients with upper abdominal symptoms should receive stool antigen or breath testing for H. pylori 4. If positive, treat with appropriate antibiotic therapy (typically PPI-based triple therapy for 10-14 days) 5.

Step 2: First-Line Interventions

Lifestyle and Dietary Modifications 3:

• Regular exercise (strong recommendation)
• First-line dietary advice focusing on trigger food identification
• Avoid insoluble fiber (wheat bran) which may worsen symptoms
• Consider soluble fiber (ispaghula 3-4 g/day, gradually increased) for IBS-type symptoms

Regarding the Probiotic Already Started 3:

• Continue the current probiotic for up to 12 weeks total to assess effectiveness
• Probiotics may help global symptoms and abdominal pain in IBS (weak recommendation, very low evidence)
• Discontinue if no improvement after 12 weeks
• No specific strain can be recommended over others, though Lactobacillus species show the strongest effects 6

Step 3: Pharmacologic Management if Symptoms Persist

For Nausea and Pain 3:

• Antispasmodics for abdominal pain (weak recommendation)
  • Common side effects: dry mouth, visual disturbance, dizziness
  • Titrate dose carefully

For Functional Dyspepsia 4:

• PPI therapy if H. pylori negative and symptoms persist
• Consider prokinetic agents if early satiety or bloating predominates

Step 4: Second-Line Treatment (If First-Line Fails)

Gut-Brain Neuromodulators 3:

• Tricyclic antidepressants (strong recommendation, moderate evidence)

  • Start amitriptyline 10 mg once daily at bedtime
  • Titrate slowly to 30-50 mg once daily
  • Explain rationale: treats visceral hypersensitivity, not depression
  • Effective for global symptoms and abdominal pain

• SSRIs (weak recommendation, low evidence)

  • Alternative if TCAs not tolerated
  • Similar counseling about mechanism required

Critical Pitfalls to Avoid

1. Don't dismiss symptoms as "just functional" without appropriate workup 1, 2. Atypical presentations of serious conditions (including appendicitis) can present with LUQ pain 7.

2. Don't continue probiotics indefinitely without reassessment 3. The evidence supports a 12-week trial only.

3. Don't use IgG food antibody testing—this is not recommended and lacks evidence 3.

4. Don't restrict diet excessively 4. Overly restrictive diets risk malnutrition and disordered eating.

5. Consider PPI discontinuation if patient is on one without clear indication 8, as PPIs can alter gut microbiota and potentially worsen IBS symptoms.

When to Escalate Care

Refer for endoscopy or specialist evaluation if 4:

• Age >50 years with new-onset symptoms
• Family history of gastric or esophageal cancer
• Persistent symptoms despite appropriate treatment
• Development of alarm features (weight loss, dysphagia, persistent vomiting, GI bleeding)

The key is systematic exclusion of serious pathology followed by evidence-based functional disorder management, with clear reassessment timelines to avoid both over-investigation and under-treatment.